Phio Pharmaceuticals Corp. (PHIO) financial statements (2021 and earlier)

Company profile

Business Address 257 SIMARANO DRIVE
MARLBOROUGH, MA 01752
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments14715413118
Cash and cash equivalents1471541358
Short-term investments     6 
Restricted cash and investments   0   
Prepaid expense    00 
Other undisclosed current assets1000000
Total current assets:15715413119
Noncurrent Assets
Operating lease, right-of-use asset01
Property, plant and equipment0000000
Long-term investments and receivables    0  
Accounts and financing receivable, after allowance for credit loss    0  
Other noncurrent assets00 0000
Total noncurrent assets:1100000
TOTAL ASSETS:16815413119
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities2222322
Accounts payable1111110
Accrued liabilities1112211
Employee-related liabilities      1
Debt 0     
Deferred revenue and credits   0
Other undisclosed current liabilities0     (1)
Total current liabilities:2222321
Noncurrent Liabilities
Long-term debt and lease obligation10     
Long-term debt, excluding current maturities0      
Operating lease, liability00
Other undisclosed noncurrent liabilities(0)      
Total noncurrent liabilities:10     
Total liabilities:3222321
Stockholders' equity
Stockholders' equity attributable to parent, including:1361421193
Common stock000 000
Additional paid in capital1171019980736648
Accumulated deficit(104)(95)(86)(79)(66)(57)(47)
Other undisclosed stockholders' equity attributable to parent    4 2
Total stockholders' equity:1361421193
Other undisclosed liabilities and equity      5
TOTAL LIABILITIES AND EQUITY:16815413119

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Revenue, net  00
Gross profit: 000000
Operating expenses(9)(9)(8)(14)(9)(10)(9)
Operating loss:(9)(9)(7)(14)(9)(10)(9)
Nonoperating income (expense)(0)00(0)000
Other nonoperating income (expense)   (0)0(0)0
Loss from continuing operations before equity method investments, income taxes:(9)(9)(7)(14)(9)(10)(9)
Other undisclosed income from continuing operations before income taxes      0
Loss from continuing operations before income taxes:(9)(9)(7)(14)(9)(10)(9)
Income tax benefit3322443
Net loss:(6)(6)(5)(12)(5)(6)(5)
Other undisclosed net loss attributable to parent(3)(3)(2) (4)(4)(3)
Net loss attributable to parent:(9)(9)(7)(12)(9)(10)(9)
Preferred stock dividends and other adjustments    (2)(0)(4)
Net loss available to common stockholders, diluted:(9)(9)(7)(12)(11)(10)(13)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(6)(6)(5)(12)(5)(6)(5)
Comprehensive loss, net of tax, attributable to parent:(6)(6)(5)(12)(5)(6)(5)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: